An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting
Clinical trial NCT06749886 · RECRUITING
Trial details
- NCT number
- NCT06749886
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-19
- Primary completion
- 2026-11-30
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.